Looking Ahead: Long-Term Outlook and Growth
At a Glance
Many appropriately selected children with DEND syndrome maintain good diabetes control with oral sulfonylurea medicine for years, but developmental and learning needs may continue. Long-term care combines diabetes monitoring with therapy, school support, and planning for adult care.
Thinking about your child’s future can bring a mix of hope and uncertainty. While DEND syndrome is a lifelong condition, long-term studies now provide a clearer picture of what to expect as your child grows into adolescence and adulthood. The most encouraging news is that for appropriately selected individuals, the switch to oral medication remains effective for many years, providing stable blood sugar without the need for insulin injections [1][2].
Long-Term Diabetes Control
Research following children for over a decade shows that the move from insulin to sulfonylureas is not just a short-term fix.
- Durable Success: In a 10-year study of children with KCNJ11 mutations, 93% were still successfully managing their diabetes with oral medication alone [1]. Similar results (about 86%) have been seen in children with ABCC8 mutations [2].
- Stable Blood Sugar: Average blood sugar levels (HbA1c - a measure of average blood sugar over several months) typically stay in a healthy range (around 6.4% to 6.5%) long-term [1][2]. However, targets must be individualized because avoiding hypoglycemia matters as much as the numerical target.
- Complication Prevention: Better glycemic control is expected to reduce complication risk, but these figures are based on specific study cohorts and are not a guarantee for an individual child [1].
While “secondary failure”—where the medication stops working after years of success—is possible, it appears to be rare. If you notice blood sugar numbers rising, your doctor will first check for changes in growth, diet, or other health factors [3][1].
Navigating Neurodevelopment
While the diabetes is often well-controlled by medication, the neurological parts of DEND syndrome (the D, E, and ND) require a different kind of long-term focus.
- Motor and Seizure Progress: Many children see significant improvements in muscle tone and a reduction in seizures after starting sulfonylureas, especially if treatment begins early [4][5].
- Ongoing Challenges: Even with excellent blood sugar control, many individuals with DEND continue to face developmental and learning challenges into adulthood [6]. These can include difficulties with coordination, attention (ADHD), and social-emotional skills, such as autism-spectrum features [6][2]. These are possible areas for assessment in some individuals, and do not definitively predict your child’s future [6][2].
- Spectrum of Outcomes: There is a wide range of how DEND and iDEND affect people. Some children with iDEND may have very mild symptoms and attend standard schools with minor support, while others with classic DEND may need lifelong assistance with daily living [7][8].
Your Long-Term Care Checklist
As your child grows, their “care team” will shift from intensive medical stabilization to long-term monitoring and support. Standard care typically includes:
| Frequency | Focus Area | Why It Matters |
|---|---|---|
| Every 3-6 Months | Endocrinology Check | To adjust medication doses as your child grows and monitor HbA1c [1]. |
| Annually | Neurodevelopmental Review | To update academic supports (like IEPs) and assess for ADHD or learning needs [9][10]. |
| Variable | Diabetes Screening | Checking kidney function and eye health (retinal exams). Timing and frequency should follow the endocrinologist’s guideline-based plan, taking into account diabetes duration, age, and glycemic history—not simply waiting until adolescence [1]. |
| Periodic | Hearing & Vision | Routine age-appropriate pediatric hearing and vision screening is recommended as standard care, and to ensure any deficits do not interfere with learning [11]. |
Early and consistent intervention—including physical, occupational, and speech therapy—is the best way to help your child reach their full potential. Your goal is to provide a “safety net” that grows with them, allowing them to focus on learning and discovery rather than just managing a condition [12][13]. As the child approaches adulthood, care will transition to adult medicine, which includes developing self-management skills, transition planning, and discussing reproductive counseling [13].
Common questions in this guide
Can children with DEND syndrome stay on oral medicine for many years?
What should we do if my child's blood sugar starts rising after treatment has worked?
Can treatment improve seizures and development in DEND syndrome?
What follow-up tests and checkups does a child with DEND syndrome need?
What school and developmental support may help a child with DEND syndrome?
How should families prepare for the move from pediatric to adult DEND care?
Get notified when new evidence is published on DEND syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
Bowman P, Sulen Å, Barbetti F, et al.
The lancet. Diabetes & endocrinology 2018; (6(8)):637-646 doi:10.1016/S2213-8587(18)30106-2.
PMID: 29880308 - 2
Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes.
Bowman P, Mathews F, Barbetti F, et al.
Diabetes care 2021; (44(1)):35-42 doi:10.2337/dc20-1520.
PMID: 33184150 - 3
Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control.
Stanik J, Dankovcikova A, Barak L, et al.
Diabetic medicine : a journal of the British Diabetic Association 2018; (35(3)):386-391 doi:10.1111/dme.13575.
PMID: 29278452 - 4
Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses.
de Gouveia Buff Passone C, Giani E, Vaivre-Douret L, et al.
Pediatric diabetes 2022; (23(6)):675-692 doi:10.1111/pedi.13376.
PMID: 35657808 - 5
Long-Term Seizure and Neurodevelopmental Outcomes of Three Children with Developmental Delay, Epilepsy, and Neonatal Diabetes (DEND) Syndrome after Early Initiation of Sulphonylurea.
Baby N, Vinayan KP, Pavithran P, et al.
Annals of Indian Academy of Neurology 2025; (28(5)):725-728 doi:10.4103/aian.aian_1097_24.
PMID: 41099379 - 6
Cognitive, Neurological, and Behavioral Features in Adults With KCNJ11 Neonatal Diabetes.
Bowman P, Day J, Torrens L, et al.
Diabetes care 2019; (42(2)):215-224 doi:10.2337/dc18-1060.
PMID: 30377186 - 7
Molecular and clinical features of KATP -channel neonatal diabetes mellitus in Japan.
Hashimoto Y, Dateki S, Hirose M, et al.
Pediatric diabetes 2017; (18(7)):532-539 doi:10.1111/pedi.12447.
PMID: 27681997 - 8
Intellectual Disability in KATP Channel Neonatal Diabetes.
Svalastoga P, Sulen Å, Fehn JR, et al.
Diabetes care 2020; (43(3)):526-533 doi:10.2337/dc19-1013.
PMID: 31932458 - 9
Patients with KCNJ11-related diabetes frequently have neuropsychological impairments compared with sibling controls.
Carmody D, Pastore AN, Landmeier KA, et al.
Diabetic medicine : a journal of the British Diabetic Association 2016; (33(10)):1380-6 doi:10.1111/dme.13159.
PMID: 27223594 - 10
ADHD, learning difficulties and sleep disturbances associated with KCNJ11-related neonatal diabetes.
Landmeier KA, Lanning M, Carmody D, et al.
Pediatric diabetes 2017; (18(7)):518-523 doi:10.1111/pedi.12428.
PMID: 27555491 - 11
Case Report: When genetic diagnosis comes late: lessons from a DEND syndrome patient successfully transitioned to sulfonylurea.
Abreu GM, Bastos de Souza R, Bernardo MC, et al.
Frontiers in clinical diabetes and healthcare 2025; (6()):1654037 doi:10.3389/fcdhc.2025.1654037.
PMID: 41169283 - 12
Neonatal Diabetes Mellitus.
Beltrand J, Busiah K, Vaivre-Douret L, et al.
Frontiers in pediatrics 2020; (8()):540718 doi:10.3389/fped.2020.540718.
PMID: 33102403 - 13
The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study.
De Franco E, Flanagan SE, Houghton JA, et al.
Lancet (London, England) 2015; (386(9997)):957-63.
PMID: 26231457
This page provides general educational information about long-term DEND syndrome care and does not constitute medical advice. Your child's endocrinology, neurology, developmental, and primary care teams should individualize treatment, screening, and school-support plans.